EDG-15400
/ Edgewise Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 25, 2026
Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF
(HEART FAILURE 2026)
- No abstract available
Compliance • Preclinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy
September 17, 2025
A Study of EDG-15400 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=108 | Recruiting | Sponsor: Edgewise Therapeutics, Inc.
New P1 trial
1 to 2
Of
2
Go to page
1